Anavex Life Sciences

Cassava Sciences

Harmony Biosciences

Denali Therapeutics

Sage Therapeutics

Neurocrine Biosciences

ACADIA Pharmaceuticals

Praxis Precision Medicine

Axsome Therapeutics

Short interest: 21.42% of float, squeeze risk: HIGH

Dilution score: 18/100 (LOW), 24.0 months cash

71 PubMed publications found for Anavex Life Sciences

Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study.

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy.

Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled Trials.

External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial.

L-Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications.

Dilution score: 28/100 (MEDIUM), 72.4 months cash

Short interest: 21.18% of float, squeeze risk: HIGH

SW convergence: 55/100 (Neutral), 2 bullish / 0 bearish signals

Short interest: 21.11% of float, squeeze risk: HIGH

70 PubMed publications found for Anavex Life Sciences

Development and initial validation of the Communication Inventory Disability - Observer Reported (CID-OR): a measure of communication in CDKL5 deficiency disorder.

SW convergence: 55/100 (Neutral), 3 bullish / 1 bearish signals

<article class="bts-verified-summary" data-ticker="AVXL">
<p>Anavex Life Sciences (AVXL) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 1 Phase 2<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>No Form 4 insider filings for AVXL were recorded at the SEC in the past 30 days<sup><a href="#fn-3">[3]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Anavex+Life+Sciences%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Anavex+Life+Sciences%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">SEC EDGAR · 0001314052 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22AVXL%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001314052

Anavex Life Sciences (AVXL) — BioTechSigns Verified Summary

Anavex Life Sciences (AVXL) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 2[1].

No Form 4 insider filings for AVXL were recorded at the SEC in the past 30 days[3].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Anavex+Life+Sciences%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Anavex+Life+Sciences%22&aggFilters=status%3Arec%2Cact
[3] SEC EDGAR, 0001314052. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22AVXL%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.